Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug
Advertisement

Related Content

India Firm Zydus Cadila Takes Teva To U.S. Court Over Risperidone APIs
India Firm Zydus Cadila Takes Teva To U.S. Court Over Risperidone APIs
Zydus Cadila Takes Teva To Virginia Court Asserting Rights Over Risperidone APIs
Zydus Cadila Takes Teva To Virginia Court Asserting Rights Over Risperidone APIs
Glenmark In Talks With Three Firms To Re-license Diabetes Drug
Glenmark In Talks With Three Firms To Re-license Diabetes Drug
Teva To Expand Presence In India
Advertisement
UsernamePublicRestriction

Register

SC069257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel